Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 25, 2026, 2:37 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 28,697 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Neurologic Diseases Clear all
Withdrawn Phase 4 Interventional

Ziprasidone vs Standard Therapy for Agitated Patients in the ED

NCT00786318
View directory record Official record
Conditions
Psychosis, Agitation, Delirium
Interventions
ziprasidone, Standard therapy
Drug
Lead sponsor
George Washington University
Other
Eligibility
18 Years to 100 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Sep 24, 2017 · Synced Jun 25, 2026, 2:37 PM EDT
Completed No phase listed Observational

Study of Taste Deficits

NCT00022997
View directory record Official record
Conditions
Taste Disorder, Healthy
Interventions
Not listed
Lead sponsor
National Institute on Deafness and Other Communication Disorders (NIDCD)
NIH
Eligibility
18 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 5, 2019 · Synced Jun 25, 2026, 2:37 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Effects of Aphasia Identification Cards on Service Workers' Comprehension of People With Aphasia

NCT06990997
View directory record Official record
Conditions
Aphasia
Interventions
Aphasia identification (ID) card
Behavioral
Lead sponsor
University of Massachusetts, Amherst
Other
Eligibility
18 Years to 59 Years
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Springfield, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Jun 25, 2026, 2:37 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Single and Multiple Ascending Dose Study of MTR-601 in Healthy Individuals

NCT06117020
View directory record Official record
Conditions
Muscle Spasticity, Hypertonia, Muscle, Cerebral Palsy, Multiple Sclerosis, Stroke, Hereditary Spastic Paraplegia, Dystonia, Spinal Cord Injuries
Interventions
MTR-601
Drug
Lead sponsor
Motric Bio
Industry
Eligibility
18 Years to 45 Years
Enrollment
89 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Jun 25, 2026, 2:37 PM EDT
Completed Phase 3 Interventional

Efficacy and Safety Study of STX209 (Arbaclofen) for the Treatment of Social Withdrawal in Children With Fragile X Syndrome

NCT01325220
View directory record Official record
Conditions
Fragile X Syndrome
Interventions
arbaclofen, Placebo
Drug
Lead sponsor
Seaside Therapeutics, Inc.
Industry
Eligibility
5 Years to 11 Years
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2011
U.S. locations
28
States / cities
Phoenix, Arizona • Long Beach, California • Sacramento, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2013 · Synced Jun 25, 2026, 2:37 PM EDT
Not listed Phase 1 Interventional

Safety Study of RTL1000 (Recombinant T Cell Receptor Ligand) in Subjects With Multiple Sclerosis

NCT00411723
View directory record Official record
Conditions
Multiple Sclerosis, Chronic Progressive, Multiple Sclerosis, Relapsing-Remitting
Interventions
RTL1000 (recombinant T cell receptor ligand), RTL1000 Placebo
Drug
Lead sponsor
Artielle ImmunoTherapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
6
States / cities
New Haven, Connecticut • Indianapolis, Indiana • Kansas City, Kansas + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 19, 2009 · Synced Jun 25, 2026, 2:37 PM EDT
Completed Phase 2Phase 3 Interventional Results available

HEALEY ALS Platform Trial - Regimen D Pridopidine

NCT04615923
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Pridopidine, Matching Placebo
Drug
Lead sponsor
Merit E. Cudkowicz, MD
Other
Eligibility
18 Years and older
Enrollment
163 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 22, 2023 · Synced Jun 25, 2026, 2:37 PM EDT
Completed Phase 1 Interventional

Vagus Nerve Stimulation to Treat Moderate Traumatic Brain Injury

NCT02974959
View directory record Official record
Conditions
Traumatic Brain Injury, Acute Brain Injuries
Interventions
gammaCore active device, gammaCore sham device
Device
Lead sponsor
CentraCare
Other
Eligibility
18 Years to 60 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 3, 2021 · Synced Jun 25, 2026, 2:37 PM EDT
Completed Phase 2 Interventional

Safety of NXY-059 for the Treatment of Patients Who Have Suffered From a Stroke

NCT00075959
View directory record Official record
Conditions
Intracerebral Hemorrhage
Interventions
NXY-059
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
64
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Fort Smith, Arkansas + 61 more
Source: ClinicalTrials.gov public record
Updated Jan 3, 2013 · Synced Jun 25, 2026, 2:37 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Effects of Whey Protein Supplements on Markers of Exercise-induced Muscle Damage in Resistance-trained Individuals

NCT05100459
View directory record Official record
Conditions
Muscle Damage, Muscle Soreness
Interventions
Pasture-raised whey protein, Conventional whey protein, Placebo
Dietary Supplement
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 40 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Bloomington, Indiana
Source: ClinicalTrials.gov public record
Updated Mar 1, 2023 · Synced Jun 25, 2026, 2:37 PM EDT
Completed Phase 1 Interventional

Satraplatin in Children and Young Adults With Refractory Solid Tumors Including Brain Tumors

NCT01259479
View directory record Official record
Conditions
Solid Tumors, Brain Tumors, Brain Metastases
Interventions
Satraplatin
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
3 Years to 25 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 4, 2018 · Synced Jun 25, 2026, 2:37 PM EDT
Not listed No phase listed Observational

Genetics of Fibromyalgia

NCT00071162
View directory record Official record
Conditions
Fibromyalgia, Irritable Bowel Syndrome, Chronic Fatigue Syndrome, Depression
Interventions
Not listed
Lead sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NIH
Eligibility
12 Years and older
Enrollment
560 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
4
States / cities
Peoria, Illinois • Cincinnati, Ohio • Cleveland, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2009 · Synced Jun 25, 2026, 2:37 PM EDT
Recruiting No phase listed Observational

A Study to Check Liver Health in Boys With XLMTM, a Serious Genetic Muscle Condition

NCT06581146
View directory record Official record
Conditions
X-Linked Myotubular Myopathy
Interventions
No Intervention
Other
Lead sponsor
Astellas Gene Therapies
Industry
Eligibility
Up to 17 Years · Male only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
6
States / cities
Chicago, Illinois • Boston, Massachusetts • Cincinnati, Ohio + 3 more
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Jun 25, 2026, 2:37 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Taste Perception, Salivary Proteins & the Oral Microbiome

NCT04107688
View directory record Official record
Conditions
Saliva Altered, Taste, Altered
Interventions
Control, CPE
Other
Lead sponsor
Rutgers University
Other
Eligibility
18 Years to 45 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated May 13, 2024 · Synced Jun 25, 2026, 2:37 PM EDT
Recruiting Not applicable Interventional

Mild Intermittent Hypoxia: A Prophylactic for Autonomic Dysfunction in Individuals With Spinal Cord Injuries

NCT05351827
View directory record Official record
Conditions
Spinal Cord Injuries, Autonomic Dysreflexia
Interventions
Mild Intermittent Hypoxia, Sham
Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 60 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 21, 2025 · Synced Jun 25, 2026, 2:37 PM EDT
Completed Phase 3 Interventional

A Study of the Effects of Pegvisomant on Growth Hormone Excess in McCune-Albright Syndrome

NCT00017927
View directory record Official record
Conditions
McCune Albright Syndrome, Polyostotic Fibrous Dysplasia
Interventions
Pegvisomant
Drug
Lead sponsor
National Institute of Dental and Craniofacial Research (NIDCR)
NIH
Eligibility
Not listed
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Jun 25, 2026, 2:37 PM EDT
Completed Phase 2 Interventional

A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Narcolepsy Type 2

NCT06555783
View directory record Official record
Conditions
Narcolepsy Type 2
Interventions
ALKS 2680, Placebo
Drug
Lead sponsor
Alkermes, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
33
States / cities
Little Rock, Arkansas • Los Angeles, California • Redwood City, California + 29 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2026 · Synced Jun 25, 2026, 2:37 PM EDT
Terminated Phase 3 Interventional

Study Describing Cognitive Processing Speed Changes in Relapsing Multiple Sclerosis Subjects Treated With Ozanimod (RPC-1063)

NCT04140305
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
RPC-1063
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 65 Years
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
56
States / cities
Birmingham, Alabama • Cullman, Alabama • Mobile, Alabama + 49 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2025 · Synced Jun 25, 2026, 2:37 PM EDT
Recruiting Not applicable Interventional

Grasp-Release Assessment of a Networked Neuroprosthesis Device

NCT05863754
View directory record Official record
Conditions
Spinal Cord Injury at C5-C7 Level, Spinal Cord Injuries, Spinal Cord Injury Cervical
Interventions
Networked Neuroprosthesis Device
Device
Lead sponsor
MetroHealth Medical Center
Other
Eligibility
16 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Jun 25, 2026, 2:37 PM EDT
Terminated Phase 3 Interventional

Double-Blind, Placebo Controlled, Phase 3 Trial of ZGN-440 (Beloranib) in Obese Subjects With Prader-Willi Syndrome

NCT02179151
View directory record Official record
Conditions
Prader-Willi Syndrome, Obesity
Interventions
ZGN-440 for Injectable Suspension, ZGN-440 Placebo for Injectable Suspension
Drug
Lead sponsor
Zafgen, Inc.
Industry
Eligibility
12 Years to 65 Years
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
15
States / cities
Sacramento, California • San Diego, California • Aurora, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Jan 25, 2017 · Synced Jun 25, 2026, 2:37 PM EDT
Active, not recruiting Phase 3 Interventional

Phase 3 Efficacy and Safety Study of GTX-102 in Pediatric Subjects With Angelman Syndrome (AS)

NCT06617429
View directory record Official record
Conditions
Angelman Syndrome
Interventions
GTX-102, Sham-LP
Drug · Procedure
Lead sponsor
Ultragenyx Pharmaceutical Inc
Industry
Eligibility
4 Years to 17 Years
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
14
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 11 more
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Jun 25, 2026, 2:37 PM EDT
Completed Phase 2 Interventional

Phase 2 Study MPC-6827 for Recurrent Glioblastoma Multiforme

NCT00892931
View directory record Official record
Conditions
Glioblastoma Multiforme
Interventions
Azixa
Drug
Lead sponsor
Myrexis Inc.
Industry
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
10
States / cities
Phoenix, Arizona • Los Angeles, California • Stanford, California + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2011 · Synced Jun 25, 2026, 2:37 PM EDT
Terminated Not applicable Interventional Results available

Testosterone Gel in Preventing Weakness Caused by Steroid Therapy in Men With Glioma

NCT00631137
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Musculoskeletal Complications
Interventions
testosterone gel applied to skin, whey powder protein
Drug · Dietary Supplement
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 120 Years · Male only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 26, 2018 · Synced Jun 25, 2026, 2:37 PM EDT
Not listed Not applicable Interventional

Unwinding Anxiety for Migraine: Pilot

NCT06150612
View directory record Official record
Conditions
Migraine, Anxiousness
Interventions
Unwinding Anxiety
Behavioral
Lead sponsor
Yeshiva University
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Dec 7, 2023 · Synced Jun 25, 2026, 2:37 PM EDT